Abiraterone Acetate for Castrate Resistant Prostate Cancer
Condition(s):Prostate CancerLast Updated:February 10, 2021Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Prostate CancerLast Updated:February 10, 2021Active, not recruiting
Condition(s):Prostatic NeoplasmsLast Updated:December 6, 2021Active, not recruiting
Condition(s):Metastatic Castration Resistant Prostate CancerLast Updated:September 13, 2019Completed
Condition(s):Prostate CancerLast Updated:June 22, 2022Active, not recruiting
Condition(s):Salivary Glands TumorsLast Updated:March 3, 2021Completed
Condition(s):Prostate CancerLast Updated:March 24, 2017Terminated
Condition(s):Prostate Cancer Metastatic; Prostate CancerLast Updated:July 5, 2022Recruiting
Condition(s):Prostate CancerLast Updated:May 12, 2017Terminated
Condition(s):Abiraterone Acetate; Gene Polymorphism; Pharmacokinetic; Metabolic Analysis; Plasma ConcentrationLast Updated:January 3, 2022Active, not recruiting
Condition(s):PharmacokineticsLast Updated:March 4, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.